Platinum Program FAQs
2026
General Questions
We are an early-stage biotech fund with a strong preference for novel therapeutics that opportunistically invests in adjacencies including medtech and diagnostics. We are disease- and modality-agnostic.
Boston/Cambridge Area
Berlin, Germany
Burlington, VT
Dallas, TX
Durham, NC
Copenhagen, Denmark
Heidelberg, Germany
Los Angeles, CA
Munich, Germany
New Haven, CT
New York City, NY
Paris, France
Philadelphia, PA
Princeton, NJ
Saclay, France
San Diego, CA
San Francisco Bay Area
San Carlos
Toronto, Canada
We aim to make up to 8 investments in 2026, with at least two investments in companies that are either currently incubating in the EU or plan to incubate in the EU, as well as two investments in companies that are planning to incubate in Toronto, and one company that is planning on incubating in Connecticut.
For the Platinum Tickets not targeted at the EU, Canada, or Connecticut, we have no geographic preferences and will award Platinum Tickets to the best investments we can find.
Out of the 8 total available tickets, we have reserved 2 for companies that are either currently incubating in the EU or plan to incubate in the EU, 2 for companies that are planning to incubate in Toronto, and 1 for a company that is planning on incubating in Connecticut.
Eligibility Questions
Yes! Our investment model prioritizes our ability to get to know companies while they are in our affiliated labs as well as providing our entrepreneurs full access to the vibrant ecosystems within them, including other entrepreneurs and pharma partners. Entirely virtual companies are not eligible for a Platinum Ticket. Rent in the lab spaces is not included in the Platinum Ticket, but may be paid using funds from the award.
Early-stage companies and their teams can take many forms. We are looking for a team with at least 1 full-time dedicated person who will be advancing the science in our affiliated labs and responsible for developing the fundraising strategy and business model. In some situations, the Platinum Ticket award has served as the catalyst for converting someone responsible for these things to full-time. In other situations, there are several people already a part of the company who divide these responsibilities among themselves. We are happy to discuss this point further, so don’t hesitate to reach out!
Many of the Platinum Program companies are academic spin-outs. Academic spin-outs should understand the licensing requirements for any relevant IP. If a license from a university is required, there should be active discussions with the university about this. In some situations, our Platinum Ticket investments are in active negotiations for an Option or License at the time of investment, and in others, the Option and/or License has already been executed.
Award Questions
All applications will be reviewed by members of the Mission BioCapital investment team. A subset will advance as finalists that will have the opportunity to pitch virtually to Mission BioCapital, AbbVie, Ono, Toronto Innovation Acceleration Programs, and Connecticut Innovations. Up to 8 investments will be selected from the finalists. All information in this process should be nonconfidential in nature.
Applicants that will move on as a finalist will receive information about the process in June 2026. All final decisions will be communicated by the end of July 2026.
The pre-seed capital is provided via an uncapped SAFE (simple agreement for future equity). As with all investments, the terms can be, and are, individually negotiated.
For companies eligible for discovery services from Alloy Therapeutics, HitGen, and/or CCRM , an equity for services agreement will be negotiated directly with Alloy Therapeutics, HitGen, or CCRM as relevant and will be awarded in addition to the seed capital.
We aim to get the Platinum Ticket winners into the labs by the end of the first quarter of 2026. We recognize that some of the Platinum Ticket winners may not have incorporated yet and/or are actively spinning out of academic institutions. For these circumstances, we can be flexible according to each winner’s needs and support the launch of the company. Mission BioCapital will discuss this process and timeline with each winner.
Mission BioCapital Platinum Program Holding LLC is making the Platinum Ticket investment. When your company successfully raises an equity round, the SAFE investment will convert to equity and the Mission BioCapital Platinum Program Holding LLC will be the entity on the capitalization table. Any equity for services provided by Alloy Therapeutics, HitGen, or other partners will be treated separately.
- Up to $500,000 of pre-seed capital provided as a SAFE investment
- Guaranteed lab space in one of Mission BioCapital’s affiliated labs located in 20 cities in the U.S. and Europe
- Drug discovery services from Alloy Therapeutics, HitGen, and CCRM to enable companies with a derisked path to lead candidate.
- HitGen services include DEL Screening and other drug discovery research services.
- Alloy Therapeutics offers up to $1M total in service for equity across all Platinum Ticket winners, including fully human monoclonal and bispecific antibody discovery, ML-driven antibody optimization and humanization, high-throughput antibody production and screening, and more.
- CCRM will provide at least 3 hours of consulting support to companies in the cell and gene space. Support can come from any affiliates within the CCRM family of companies (CCRM, OmniaBio, LineaBio, CATTI, CCRM Enterprises) and can be tailored to the needs of the company, including feedback on product development, manufacturing considerations, path to GMP manufacturing, pitch deck feedback, sources of non-dilutive funding, feedback on indication selection, considerations for cell line development/selection, and high level market analyses
- Legal and business services to form and run your new business including: corporate entity formation, accounting and finance services, contract review and negotiation, intellectual property expertise, competitive intelligence assessment, and scientific mentoring and business development mentoring and guidance.
- Mentorship from experts at Mission BioCapital, AbbVie, Ono, Alloy Therapeutics, HitGen and other companies across Mission BioCapital’s corporate network
- Goodwin is delighted to offer Platinum Program winners the following benefits and additional resources that particular winners may need to optimize their legal support:
- Minimum of three hours per Platinum Ticket investment winner of advisory services with focus on typical company formation and launch challenges including: Corporate organization and formation advice as well as governance advice and Board minutes and consents; day-to-day advice on typical questions; cap tables, e.g., founder equity and compensation topics, such as option plans, and etc.; support for SAFEs and convertible notes; and negotiating relevant contracts (e.g., leases, academic IP licenses, etc.) and access to standard form agreements used by startup companies.
- Free incorporation & filing of associated legal documents (excluding filing fees), CTA filings to the extent applicable (i.e., ex-US companies and founders).
- In continued capacity as company counsel: deferral until specified funding; 10% discount on fees; and up to 25 free billable hours of free first-year business law associate or tech specialist time (tech specialists are intellectual property practitioners with advance science degrees).
- Van den Boom & Associates offers expert guidance to help companies develop and implement scalable financial and G&A operations including contracts management, accounts payable, payroll, financial reporting, investor reporting, financial modeling/cash runway, and diligence support.
The Platinum Ticket guarantees a lab bench in our affiliated incubators, but rent is not included. Rent is negotiated through a lease with the incubator selected by the winner. Paying rent from the pre-seed capital is an acceptable use of funds.
A typical lease is approximately 1 year and is individually negotiated with the incubator that the Platinum Ticket investment chooses.
Application Questions
Platinum Program Applications for 2026 Open April 1 !
This application is currently inactive. The questions below are shared as a preview for prospective applicants. It allows you to review required questions and materials in advance of the Spring 2026 application cycle. Please check back in spring 2026 when applications reopen.
1. Company Name
2. Have you formerley incorporated the company?
3. Year Founded:
4. Business Address
5. Primary Contact Email
6. Company Summary
1. Technology Sector: (Select all that apply)
2. Therapeutic Modality: (select all that apply)
3. Therapeutic Area: (select all that apply)
4. Primary Technology Sector: (select one)
5. Primary Therapeutic Modality: (select one)
6. Primary Therapeutic Area: (select one)
1. Please indicate which incubator location(s) you?re interested in (select at least one):
2. Select one or both of the following:
3. University Affiliation (Please Enter Other if Institution is Not Listed)
4. Is your company an academic spin-out?
5. Description of academic relationship (optional):
1. First Name of Founder
2. Last Name of Founder
3. Current title/Role of Founder with Company
4. What percentage of work time are you committing to this company (i.e., are you full-time)?
5. [Optional] If not 100%, what other obligations do you have?
6. Mission BioCapital strongly encourages under-represented founders to apply. If you identify as under-represented in the biotech industry please self-identify here*: (check all applicable boxes)
7. List Additional Founders
1. How much money, if any, have you raised to date?
2. Currency Type
3. Describe the source (e.g., non-dilutive grants, SBIR/STTR, angel, venture capital, debt, friends and family, revenue/income, etc.) of capital raised to date.
- Up to $500,000 of pre-seed capital provided as a SAFE investment
- Guaranteed lab space in one of Mission BioCapital’s affiliated labs located in 20 cities in the U.S. and Europe
- Drug discovery services from Alloy Therapeutics and HitGen to enable companies with a derisked path to lead candidate.
- HitGen services include DEL Screening and other drug discovery research services.
Alloy offers up to $1M total in service for equity across all Platinum Ticket winners, including fully human monoclonal and bispecific antibody discovery, ML-driven antibody optimization and humanization, high-throughput antibody production and screening, and more.
- Legal and business services to form and run your new business including: corporate entity formation, accounting and finance services, contract review and negotiation, intellectual property expertise, competitive intelligence assessment, and scientific mentoring and business development mentoring and guidance.
- Mentorship from experts at Mission BioCapital, AbbVie, Ono, Alloy Therapeutics, HitGen and other companies across Mission BioCapital’s corporate network
- Goodwin is delighted to offer Platinum Program winners the following benefits and additional resources that particular winners may need to optimize their legal support:
- Minimum of three hours per Platinum Ticket investment winner of advisory services with focus on typical company formation and launch challenges including: Corporate organization and formation advice as well as governance advice and Board minutes and consents; day-to-day advice on typical questions; cap tables, e.g., founder equity and compensation topics, such as option plans, and etc.; support for SAFEs and convertible notes; and negotiating relevant contracts (e.g., leases, academic IP licenses, etc.) and access to standard form agreements used by startup companies.
- Free incorporation & filing of associated legal documents (excluding filing fees), CTA filings to the extent applicable (i.e., ex-US companies and founders).
- In continued capacity as company counsel: deferral until specified funding; 10% discount on fees; and up to 25 free billable hours of free first-year business law associate or tech specialist time (tech specialists are intellectual property practitioners with advance science degrees).
- Van den Boom & Associates offers expert guidance to help companies develop and implement scalable financial and G&A operations including contracts management, accounts payable, payroll, financial reporting, investor reporting, financial modeling/cash runway, and diligence support.
- Upload a non-confidential presentation of your company.
1. What are you hoping to gain from participating in the Platinum Program, in addition to funds?
2. Have you participated in any accelerator/mentoring programs and/or any business pitch/plan programs in the past?
3. How did you hear about this opportunity?
